Volume 7.05 | Feb 12

Prostate Cell News 7.05 February 12, 2016
Prostate Cell News
     In this issue: Publications | Reviews | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  PCN on Twitter
Sequencing Reveals Molecular Underpinnings of Aggressive Prostate Cancer Subtype
A subset of treatment-resistant prostate cancer pathologically resembles small cell lung cancer rather than typical prostate cancer, investigators discovered in a new study. Their findings may lead to more effective ways to diagnose and treat neuroendocrine prostate cancer. [Press release from Weill Cornell Medicine discussing online prepublication in Nature Medicine] Press Release | Abstract
Free Sample: TeSR™2 Defined, Feeder-Free and Xeno-Free Human ES and iPS Cell Medium
PUBLICATIONS (Ranked by impact factor of the journal)

Potential Role for YB-1 in Castration-Resistant Prostate Cancer and Resistance to Enzalutamide through the Androgen Receptor V7
Researchers aimed to elucidate the kinome in castration-resistant prostate cancer as well as the role of key molecules. [J Natl Cancer Inst] Abstract

Integration of Lipidomics and Transcriptomics Unravels Aberrant Lipid Metabolism and Defines Cholesteryl Oleate as Potential Biomarker of Prostate Cancer
Scientists performed lipidomics and transcriptomics in paired prostate cancer tumor and adjacent nontumor tissues, followed by external validation of biomarker candidates. [Sci Rep] Full Article

Role of Protease-Activated Receptor 2 in the Development of Lower Urinary Tract Dysfunction
Researchers reported that the mast cell-tryptase-protease-activated receptor 2 (PAR2) axis plays a critical role in the development of chronic pain in experimental autoimmune prostatitis, a mouse model of chronic prostatitis/chronic pelvic pain syndrome. They therefore examined whether PAR2 activation mediates lower urinary tract dysfunction. [J Urol] Abstract

Prostate Cancer-Derived Cathelicidin-Related Antimicrobial Peptide Facilitates Macrophage Differentiation and Polarization of Immature Myeloid Progenitors to Protumorigenic Macrophages
To investigate protumorigenic role(s) of cathelicidin-related antimicrobial peptide (CRAMP), a murine orthologue of leucin leucin 37, investigators compared tumor growth kinetics between mouse prostate cancer cell lines with and without CRAMP expression in immunocompetent mice. [Prostate] Abstract


The Use of a Gas Chromatography-Sensor System Combined With Advanced Statistical Methods, Towards the Diagnosis of Urological Malignancies
Researchers proposed a gas chromatography-sensor algorithm system for classifying urine samples from patients with urological symptoms. The pilot study included 155 men presenting to urology clinics, 58 were diagnosed with prostate cancer, 24 with bladder cancer and 73 with hematuria and or poor stream, without cancer. [J Breath Res] Abstract | Press Release

The ERSPC Risk Calculators Significantly Outperform the PCPT 2.0 in the Prediction of Prostate Cancer; a Multi-Institutional Study
To analyze the performance of the Prostate Cancer Prevention Trial Risk Calculator (PCPT-RC) and two iterations of the European Randomized Study of Screening for Prostate Cancer Risk Calculator (ERSPC-RC), one of which incorporates prostate volume and another which incorporates prostate volume and the Prostate Health Index in a referral population. [BJU Int] Abstract

The Prognostic Impact of Serum Testosterone during Androgen-Deprivation Therapy in Patients with Metastatic Prostate Cancer and the SRD5A2 Polymorphism
Scientists investigated the relationship between androgen-deprivation therapy (ADT) serum testosterone levels or body mass index and the prognosis among men treated with primary ADT for metastatic prostate cancer. [Prostate Cancer Prostatic Dis] Abstract

Stratification of Aggressive Prostate Cancer from Indolent Disease-Prospective Controlled Trial Utilizing Expression of 11 Genes in Apparently Benign Tissue
Investigators evaluated the diagnostic power of molecular markers in men with a clinical suspicion of prostate cancer using apparently benign areas as targeted by magnetic resonance imaging. [Urol Oncol] Abstract

Cryopreservation Media for Stem Cells - Learn More!
Role of Taxanes in Advanced Prostate Cancer
Docetaxel, as first-line therapy, and cabazitaxel, as second-line therapy, have demonstrated to increase the survival in castration-resistant prostate cancer. The results from last studies either on high-risk localized disease or on androgen-sensitive tumors demonstrate the increasing role of taxanes at earlier states of prostate cancer. [Clin Transl Oncol] Abstract

Visit our reviews page to see a complete list of reviews in the prostate cell research field.
American Urological Association and Chesapeake Urology Expand Partnership with Urology Care Foundation to Advance Prostate Cancer Research through $1 Million Endowment
The American Urological Association, the Urology Care Foundation and Chesapeake Urology Associates have strengthened their commitment to securing the future of prostate cancer care through an enhanced $1 million partnership designed to advance prostate cancer research and improve the care for men with or at risk for the disease. [The American Urological Association] Press Release

PDS Biotechnology Signs Agreement with National Cancer Institute
PDS Biotechnology announced that the company has signed a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI). Under the CRADA, PDS and NCI aim to co-develop several immunotherapies through Phase II clinical trials utilizing combinations of Versamune® with NCI- and PDS-sourced tumor-related proteins or their fragments recognized by the immune system in prostate, breast, and HPV-related cancers. [PDS Biotechnology Corporation] Press Release

AUA Announces 2016 Annual Award Winners
The American Urological Association (AUA) announced the list of 2016 award recipients who will be honored at the Association’s upcoming Annual Meeting. These physician researchers and educators are being honored for their contributions to the field of medicine, the specialty of urology and the AUA. [The American Urological Association] Press Release

From our sponsor: Learn about air-liquid interface culture for respiratory research. Watch the video.
National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
NEW Tumor Microenvironment and Signaling
April 3-6, 2016
Heidelberg, Germany

Visit our events page to see a complete list of events in the prostate cell community.
NEW PhD Position – Experimental Radiotherapy in Prostate Cancer (Katholieke Universiteit Leuven)

NEW Postdoctoral Fellowship – Cancer Epigenomics (Princess Margaret Cancer Centre)

NEW Postdoctoral Fellowship – Prostate Cancer Biology (Medical University of South Carolina )

Postdoctoral Fellowship – Prostate Cancer and Cancer Metabolism (Cleveland Clinic)

Post-Doc Fellowship – Metastasis of Cancer (University of Arizona Cancer Center)

Post-Doc Fellowship – Molecular Imaging for Prostate Cancer (Case Western Reserve University)

Post-Doc Fellowship/Staff Scientist – Prostate Cancer Epidemiology (Memorial Sloan Kettering Cancer Center)

Faculty Position – Urology Research (Mayo Clinic)

Post-Doc Fellowship – Cancer Stem Cell Biology (Weill Cornell Medical College)

Postdoctoral Research Fellow – Cell Cycle Control and Tumorigenesis (Fred Hutchinson Cancer Research Center)

Division Head – Medical Oncology (Fred Hutchinson Cancer Research Center)

Recruit Top Talent: Reach more than 60,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Prostate Cell News? Click here to submit!

Comments or suggestions? Submit your feedback here
Learn more about Prostate Cell News: Archives | Events | Contact Us